303 related articles for article (PubMed ID: 30712978)
1. Implications and Future Perspectives of AGEs in PCOS Pathophysiology.
Merhi Z; Kandaraki EA; Diamanti-Kandarakis E
Trends Endocrinol Metab; 2019 Mar; 30(3):150-162. PubMed ID: 30712978
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between advanced glycation end products and vitamin D: A compelling paradigm for the treatment of ovarian dysfunction in PCOS.
Merhi Z
Mol Cell Endocrinol; 2019 Jan; 479():20-26. PubMed ID: 30170183
[TBL] [Abstract][Full Text] [Related]
3. Androgens Increase Accumulation of Advanced Glycation End Products in Granulosa Cells by Activating ER Stress in PCOS.
Azhary JMK; Harada M; Kunitomi C; Kusamoto A; Takahashi N; Nose E; Oi N; Wada-Hiraike O; Urata Y; Hirata T; Hirota Y; Koga K; Fujii T; Osuga Y
Endocrinology; 2020 Feb; 161(2):. PubMed ID: 32020188
[TBL] [Abstract][Full Text] [Related]
4. Advanced glycation end products and their relevance in female reproduction.
Merhi Z
Hum Reprod; 2014 Jan; 29(1):135-45. PubMed ID: 24173721
[TBL] [Abstract][Full Text] [Related]
5. Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Rutkowska AZ; Diamanti-Kandarakis E
Curr Pharm Des; 2016; 22(36):5558-5571. PubMed ID: 27412301
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycation end products: A link between metabolic and endothelial dysfunction in polycystic ovary syndrome?
Pertynska-Marczewska M; Diamanti-Kandarakis E; Zhang J; Merhi Z
Metabolism; 2015 Nov; 64(11):1564-73. PubMed ID: 26386695
[TBL] [Abstract][Full Text] [Related]
7. An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients.
Liao Y; Huang R; Sun Y; Yue J; Zheng J; Wang L; Tao T; Ma J; Li S; Liu W
Reprod Biol Endocrinol; 2017 Jan; 15(1):9. PubMed ID: 28125989
[TBL] [Abstract][Full Text] [Related]
8. Serum and follicular fluid levels of soluble receptor for advanced glycation end-products in women with and without polycystic ovary syndrome.
Emami N; Alizadeh A; Maleki-Hajiagha A; Dizavi A; Vesali S; Moini A
J Ovarian Res; 2023 Jun; 16(1):127. PubMed ID: 37391740
[TBL] [Abstract][Full Text] [Related]
9. Polycystic ovary syndrome and environmental toxins.
Rutkowska AZ; Diamanti-Kandarakis E
Fertil Steril; 2016 Sep; 106(4):948-58. PubMed ID: 27559705
[TBL] [Abstract][Full Text] [Related]
10. Contribution of Advanced Glycation End Products to PCOS Key Elements: A Narrative Review.
Mouanness M; Nava H; Dagher C; Merhi Z
Nutrients; 2022 Aug; 14(17):. PubMed ID: 36079834
[TBL] [Abstract][Full Text] [Related]
11. AGEs-related dysfunctions in PCOS: evidence from animal and clinical research.
Tatone C; Di Emidio G; Placidi M; Rossi G; Ruggieri S; Taccaliti C; D'Alfonso A; Amicarelli F; Guido M
J Endocrinol; 2021 Sep; 251(2):R1-R9. PubMed ID: 34448729
[TBL] [Abstract][Full Text] [Related]
12. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS).
Tantalaki E; Piperi C; Livadas S; Kollias A; Adamopoulos C; Koulouri A; Christakou C; Diamanti-Kandarakis E
Hormones (Athens); 2014; 13(1):65-73. PubMed ID: 24722128
[TBL] [Abstract][Full Text] [Related]
13. Relationship between Advanced Glycation End Products and Steroidogenesis in PCOS.
Garg D; Merhi Z
Reprod Biol Endocrinol; 2016 Oct; 14(1):71. PubMed ID: 27769286
[TBL] [Abstract][Full Text] [Related]
14. Advanced Glycation End Products: Link between Diet and Ovulatory Dysfunction in PCOS?
Garg D; Merhi Z
Nutrients; 2015 Dec; 7(12):10129-44. PubMed ID: 26690206
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries.
Diamanti-Kandarakis E; Piperi C; Patsouris E; Korkolopoulou P; Panidis D; Pawelczyk L; Papavassiliou AG; Duleba AJ
Histochem Cell Biol; 2007 Jun; 127(6):581-9. PubMed ID: 17205306
[TBL] [Abstract][Full Text] [Related]
16. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
Diamanti-Kandarakis E; Katsikis I; Piperi C; Kandaraki E; Piouka A; Papavassiliou AG; Panidis D
Clin Endocrinol (Oxf); 2008 Oct; 69(4):634-41. PubMed ID: 18363886
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end-products and its soluble receptor are not independent predictors of incident dysglycaemia or metabolic syndrome in women with polycystic ovary syndrome: a prospective observational study.
Tong YW; Ko JKY; Lam KSL; Tam S; Lee VCY; Ho PC; Ng EHY; Li RHW
Reprod Biol Endocrinol; 2023 May; 21(1):41. PubMed ID: 37165411
[TBL] [Abstract][Full Text] [Related]
18. Correlation between follicular fluid levels of sRAGE and vitamin D in women with PCOS.
Garg D; Grazi R; Lambert-Messerlian GM; Merhi Z
J Assist Reprod Genet; 2017 Nov; 34(11):1507-1513. PubMed ID: 28825156
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease.
Prasad K; Tiwari S
Curr Pharm Des; 2017; 23(6):937-943. PubMed ID: 27719648
[TBL] [Abstract][Full Text] [Related]
20. Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women.
Pertynska-Marczewska M; Merhi Z
Reprod Sci; 2015 Jul; 22(7):774-82. PubMed ID: 25228634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]